CTABF - Canntab Therapeutics Limited

Other OTC - Other OTC Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 58.06M
Enterprise Value 37.67M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-63.25%
S&P500 52-Week Change 321.87%
52 Week High 30.8600
52 Week Low 30.3028
50-Day Moving Average 30.3538
200-Day Moving Average 30.4337

Share Statistics

Avg Vol (3 month) 3689
Avg Vol (10 day) 359
Shares Outstanding 525.31M
Float 17.31M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Apr. 30, 2016
Ex-Dividend Date 4Mar. 8, 2016
Last Split Factor (new per old) 2200/1
Last Split Date 3Apr. 20, 2018

Financial Highlights

Currency in CAD.

Fiscal Year

Fiscal Year Ends May 31, 2019
Most Recent Quarter (mrq)Aug. 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-38.80%
Return on Equity (ttm)-85.49%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)1,233.30%
Gross Profit (ttm)143.61k
EBITDA N/A
Net Income Avi to Common (ttm)N/A
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)18.45
Current Ratio (mrq)2.40
Book Value Per Share (mrq)N/A

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A